Phone: 4125396258


Program: PhD
Track: Medicinal Chemistry
Advisor: Xiang-Qun (Sean) Xie, PhD, EMBA

Yuemin Bian
PhD Student in Pharmaceutical Science

University of Pittsburgh Since August 2015
Program: PhD in Pharmaceutical Science,
Research of Interest: Computational Chemistry & biology, Fragment-based drug design, GPCR allosteric modulation, Cannabinoid receptors
Core Courses: Medicinal Chemistry, BioStatistics with SAS, STATA, and SPSS, Pharmaceutical Analysis, Pharmacology and Therapeutics, Foundations Pharmaceutical Science
GPA: 3.786/4.000
NIH Center of Excellence for CDAR Summer Research Presentation Award 2017 (09/2017)
NIH Center of Excellence for CDAR 2018 Spring Outstanding Research Achievements (01/2018)

Rutgers, the State University of New Jersey January 2015 – May 2015
Program: Studying in Medicinal Chemistry as a Visiting Scholar
Project: The Synthesis and Evaluation of Potential inhibitors of cystine crystal growth for cystinuria
Scholarship ($1600 per month) from China Scholarship Council (From 1/2015 To 5/2015)

China Pharmaceutical University September 2011 – June 2015
Major: Medicinal Chemistry
Degree: Bachelor of Science
Core Courses: Medicinal Chemistry, Organic Chemistry, Analytical Chemistry, Pharmacology, Microbiology, Pharmacokinetics, Pharmacodynamics, Computer-aided Drug Design, Biochemistry and Molecular Biology, Inorganic Chemistry, Physical Chemistry
GPA: 84.12/100

Yuemin Bian, Xibing He, Yankang Jing, Lirong Wang, Junmei Wang, and Xiang-Qun Xie* Computational systems pharmacology analysis of cannabidiol: a combination of chemogenomics-knowledgebase network analysis and integrated in silico modeling and simulation. Acta Pharmacologica Sinica, in press, accepted on 04/28/2018
Yuemin Bian, Xiang-Qun (Sean) Xie* Computational fragment-based drug design: current trends, strategies, and applications. AAPS J. (2018) 20(3):59.
Yuemin Bian, Zhiwei Feng, Peng Yang, Xiang-Qun (Sean) Xie* Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5. AAPS J. 2017;19(4):1235-48
Yankang Jing, Yuemin Bian, Xiang-Qun Xie* Deep Learning for Drug Design: an artificial Intelligence paradigm for drug discovery in the big-data era. AAPS J. 2018,20(3):58.
Zhu, Xiong; Zhou, Jinpei; Zhu, Yan; Hu, Xiaowen; Bian, Yuemin; Hu, Xinting; Tao, Zhuo; Gao, Cong; Huang, Wenlong. "Synthesis and Biological Activities of Sulfinyl Acetamide Derivatives for Narcolepsy Treatment." Letters in Drug Design & Discovery10.3 (2013): 266-270.

Posters and Presentations
Yuemin Bian et al. “Computational Chemogenomics-based Targets Identification and Protein Binding Modes Analysis for Cannabidiol” Science 2017, United States, Pittsburgh, 2017
Yuemin Bian “Fragment-based Discovery of Allosteric Modulators on Metabotropic Glutamate Receptor 5” Pharmaceutical Science World Congress, Stockholm, Sweden, 2017
Yuemin Bian et al. “Cloud Computing and Diseases Domain-Specific Chemogenomics Knowledgebases for Systems Pharmacotherapy and Personalized Medicine” 2016 Posters, Professors, and Progress, United States, Pittsburgh, 2016